Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor
4.8
(629)
Write Review
More
$ 27.50
In stock
Description
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Early Adverse Events predict Survival Outcomes in HER2-positive
Everolimus and its role in hormone-resistant and trastuzumab
Neoadjuvant Therapy in HER2-Positive Breast Cancer: Ready for
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Cancers, Free Full-Text
Lapatinib and lapatinib plus trastuzumab therapy versus
Early Lapatinib-Induced Skin Rash Predicts Better Survival With
A Phase 1B open-label study of gedatolisib (PF-05212384) in
Lapatinib and lapatinib plus trastuzumab therapy versus
Related products
